

INDEX

GENERAL INTRODUCTION.....	1
1.1. CELL DEATH.....	3
1.1.1. Apoptosis.....	4
1.1.2. Main apoptotic pathways.....	5
1.1.2.1. Extrinsic apoptotic pathway.....	6
1.1.2.2. Intrinsic apoptotic pathway.....	7
1.2. THE BCL-2 PROTEIN FAMILY.....	10
1.2.1. Structure of Bcl-2 proteins.....	12
1.2.2. Molecular mechanisms of Bcl-2 family regulation.....	14
1.3. SUBCELLULAR DISTRIBUTION OF BCL-2 FAMILY PROTEINS.....	18
1.3.1. Bcl-2 transmembrane domains in the context of full-length proteins: membrane targeting and functional role.....	22
1.4. BCL-2 PROTEIN FAMILY IN DISEASE.....	29
1.4.1. Targeting Bcl-2 proteins in cancer therapy.....	29
1.4.2. Druggability of transmembrane domains.....	32
OBJECTIVES.....	38
Chapter I Mcl-1 and Bok Transmembrane Domains: Unexpected	
Players in the Modulation of Apoptosis.....	42
3.1. INTRODUCTION.....	45
3.2. MATERIALS AND METHODS.....	48
3.2.1. Cell cultures.....	48
3.2.2. Bcl transmembrane domains oligomerization assays.....	48
3.2.3. Immunoblotting.....	50
3.2.4. Subcellular fractionation.....	51
3.2.5. Confocal live-cell imaging.....	52

3.2.6. Determination of caspase 3/7 activity.....	53
3.2.7. Mitochondrial depolarization assay.....	54
3.2.8. Lactate dehydrogenase release.....	55
3.2.9. Immunoprecipitation.....	56
3.2.10. Bok silencing.....	56
3.2.11. Molecular dynamics simulations.....	57
3.2.12. In situ proximity ligation assay.....	57
3.2.13. Mcl-1 somatic mutations.....	58
3.2.14. Statistical analysis.....	59
3.2.15. Software.....	60
3.3. RESULTS.....	60
3.3.1. The Mcl-1 TMD oligomerizes in intracellular membranes.....	60
3.3.2. The Mcl-1 TMD induces cell death by competition with the full-length Mcl-1 protein.....	65
3.3.3. The Mcl-1 TMD induces apoptosis in a Bax/Bak independent and Bok dependent manner.....	69
3.3.4. Molecular simulation studies of Mcl-1 TMD membrane interactions.....	74
3.3.5. The Mcl-1 TMD facilitates the Bok TMD mitochondrial localization.....	79
3.3.6. The relevance of Mcl-1 TMD somatic mutations.....	83
3.4. DISCUSSION.....	87
3.5. CONCLUSIONS.....	90
Chapter II High Throughput Screening to Discover Inhibitors of Mcl-1/Bok Transmembrane Interactions.....	92
4.1. INTRODUCTION.....	93
4.2. MATERIALS AND METHODS.....	97
4.2.1. Cell culture.....	97

4.2.2. Primary and secondary high-throughput screening.....	97
4.2.3. Bcl TMD specificity.....	98
4.2.4. Statistical analysis.....	99
4.2.5. Software.....	99
4.3. RESULTS.....	100
4.3.1. Development of high-throughput screening to identify inhibitors of Mcl-1 and Bok TMDs hetero oligomerization.....	100
4.3.2. Preliminary identification of three inhibitors of Mcl-1 and Bok TMDs hetero-oligomerization.....	106
4.4. DISCUSSION.....	115
4.5. CONCLUSIONS.....	118
 Chapter III Somatic Mutations of Bcl-2 and Bcl xL Transmembrane	
Domains: Molecular and Functional Analysis.....	121
5.1. INTRODUCTION.....	124
5.2. MATERIALS AND METHODS.....	125
5.2.1. Cell culture.....	125
5.2.2. Bcl-2 and Bcl-xL somatic mutants.....	126
5.2.3. BiFC-based screen of Bcl-2 and Bcl-xL TMD somatic mutants oligomerization.....	129
5.2.4. Caspase 3/7 activity of the Bcl-2 and Bcl-xL TMD somatic mutations.....	129
5.2.5. Immunoblotting.....	131
5.2.6. Subcellular fractionation.....	131
5.2.7. Statistical analysis.....	131
5.2.8. Software.....	131
5.3. RESULTS AND DISCUSSION.....	132

5.3.1. Analysis of cancer mutations within the Bcl-xL TMD.....	132
5.3.2. Cancer mutations in the Bcl-2 TMD alter the oligomerization state and the antiapoptotic function.....	139
5.4. CONCLUSIONS.....	149
CONCLUSIONS.....	124
BIBLIOGRAPHY.....	156